||Evaluation of the Potential Carcinogenicity of Melphalan (148-82-3).
||Syracuse Research Corp., NY. ;Environmental Monitoring and Services, Inc., Washington, DC.;Environmental Protection Agency, Washington, DC. Office of Health and Environmental Assessment.
||EPA-68-03-3112 ;EPA-68-03-3182; EPA/600/8-91/146 ; OHEA-C-073-121
Risk assessment ;
Public health ;
Hazardous materials ;
Dose-response relationships ;
||Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy.
Melphalan is a probable human carcinogen, classified as weight-of-evidence Group B1 under the EPA Guidelines for Carcinogen Risk Assessment. Evidence on potential carcinogenicity from animal studies is 'Sufficient', and the evidence from human studies is 'Limited'. The 'Limited' designation given to the human evidence for carcinogenicity is based upon three independent series of cases of multiple myelomas that were treated with melphalan. The potency factor (F) for melphalan is estimated to be 810.0 (mg/kg/day)-1, placing it in potency group 1 according to the CAG's methodology for evaluating potential carcinogens. Combining the weight-of-evidence group and the potency group, melphalan is assigned a 'HIGH' hazard ranking.